IL-17A Antibodies Targeting Specific Epitopes for Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for specific antibodies that can effectively inhibit the effects of IL-17A and its induced activity, particularly to treat autoimmune and inflammatory disorders such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Innovation Solution
Development of isolated antibodies or proteins with antigen-binding portions that specifically bind to homodimeric IL-17A and heterodimeric IL-17AF, while not binding to homodimeric IL-17F, thereby inhibiting IL-17A-induced activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are designed to specifically bind to IL-17A and IL-17AF, then therapeutic effectiveness against autoimmune disorders is improved, but selectivity against IL-17F becomes more difficult to achieve
Solution Approach 1:
The antibody design focuses on targeting specific epitopes on IL-17A and IL-17AF that are distinct from IL-17F binding sites. By segmenting the recognition task into specific epitope-targeting regions (CDRs) rather than attempting to recognize entire cytokine structures, the patent achieves selective binding to intended targets while avoiding cross-reactivity with IL-17F
Solution Approach 2:
The patent employs local quality by designing CDR regions with specific amino acid sequences that are optimized for binding to particular epitopes on IL-17A and IL-17AF. The variable regions contain tailored sequences (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 with specific identities) that provide localized binding affinity and specificity, allowing discrimination between similar cytokines
2Adaptability or versatility
If broad-spectrum immunosuppressants are used to treat autoimmune disorders, then multiple symptoms can be addressed, but side effects and lack of specificity increase
Solution Approach 1:
The patent extracts and targets the specific pathological pathway involving IL-17A and IL-17AF by designing antibodies that selectively neutralize these cytokines. This extracts the therapeutic action from broad immunosuppression and concentrates it on the specific IL-17 signaling pathway, thereby maintaining treatment coverage for IL-17-mediated diseases while eliminating side effects associated with suppressing other immune functions
Solution Approach 2:
The antibody serves as an intermediary that specifically binds to and neutralizes IL-17A and IL-17AF, preventing them from activating their receptors and initiating inflammatory cascades. This intermediary approach allows selective intervention in the IL-17 pathway without affecting other cytokine systems, providing targeted therapy versus broad immunosuppression
Data Source
AI summary
The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.